WuXi Partners with Swedish Firm to Establish New Contract Manufacturer

January 26, 2018 PAO-M01-18-NI-043

Wuxi Griffin will be western-managed but located in China.

China-based Wuxi Fortune Pharmaceutical and Sweden-based sterile filling and medical device validation and production company, SialoCarb, have formed Wuxi Griffin Pharmaceutical, a new contract manufacturer focused on the aseptic fill and finish of sterile pharmaceuticals. 

The company will be headed by Torgny Lundgren. Wuxi Griffin will manufacture monoclonal antibodies, vaccines, vaccine, recombinant proteins and biosimilars, as well as traditional small-molecule drugs. The 7,450-ft2 aseptic fill/finish facility includes restricted access barrier (RABS) and isolator technologies and has equipment for the production of both clinical and commercial material.

"Complying to global GMP gives us an advantage, as the requirements of Chinese customers wanting Western quality products are met. We also assist Western pharmaceutical companies wanting accelerated access to the Chinese market," said Lundgren.

 

Guy Tiene

Guy supports the success of life science organizations by identifying synergies across research, content, marketing and communications resources to drive value for clients. With over 30 years of education and marketing experience and 18 years in the life sciences alone, Guy leads our editorial standards for client content, Pharma’s Almanac and Nice Insight research-based industry content as well as external communications for clients. Having served as head of global marketing and communications for a CMO, he also brings critical insight and guidance to all communications. Guy holds a Masters degree from Columbia University.

Q: